Cardiac surgery following transcatheter aortic valve replacement.


Journal

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
ISSN: 1873-734X
Titre abrégé: Eur J Cardiothorac Surg
Pays: Germany
ID NLM: 8804069

Informations de publication

Date de publication:
02 11 2021
Historique:
received: 08 10 2020
revised: 12 02 2021
accepted: 09 03 2021
pubmed: 23 5 2021
medline: 15 12 2021
entrez: 22 5 2021
Statut: ppublish

Résumé

The objective of this study was to retrospectively analyse surgical outcomes of patients undergoing secondary cardiac surgery after initial transcatheter aortic valve replacement (TAVR). Between December 2012 and February 2020, a total of 41 consecutive patients underwent cardiac surgery after a TAVR procedure at our institution. Patients who underwent emergency operations due to periprocedural complications such as ventricular rupture and TAVR dislocation were excluded from this study (n = 12). Thus, 29 patients were included in the analysis. Data are presented as medians (25th-75th quartiles) or as absolute numbers (percentages). The median age was 76 years (68-80); 58.6% were men. The median time to a secondary conventional procedure was 23 months (8-40), with 8 patients requiring surgical intervention within the first year post TAVR. The indications for secondary conventional procedures were prosthesis endocarditis (n = 15), prosthesis degeneration or dysfunction (n = 7) and progression of valvular, aortic or coronary artery disease (n = 7). Surgical redo aortic valve replacement was performed in 24 patients (82.8%). No complications involving the aortic root or the aortomitral continuity were observed. The operative mortality was 10.3%. Extracorporeal life support was required in 3 patients (10.3%) for a median duration of 3 days (3-3 days). No adverse cerebrovascular events were observed postoperatively. Postoperatively, 4 patients (13.8%) required a pacemaker and 7 patients (24.1%) required renal replacement therapy. Overall survival at 1 year was 83.0%. Conventional cardiac surgical procedures following TAVR are feasible with reasonable results and a low complication rate.

Identifiants

pubmed: 34021322
pii: 6280187
doi: 10.1093/ejcts/ezab217
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1149-1155

Commentaires et corrections

Type : CommentIn

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Auteurs

Shekhar Saha (S)

Department of Cardiac Surgery, LMU University Hospital, Munich, Germany.

Sven Peterss (S)

Department of Cardiac Surgery, LMU University Hospital, Munich, Germany.

Christoph Mueller (C)

Department of Cardiac Surgery, LMU University Hospital, Munich, Germany.

Simon Deseive (S)

Department of Cardiology, LMU University Hospital, Munich, Germany.

Sebastian Sadoni (S)

Department of Cardiac Surgery, LMU University Hospital, Munich, Germany.

Jörg Hausleiter (J)

Department of Cardiology, LMU University Hospital, Munich, Germany.

Steffen Massberg (S)

Department of Cardiology, LMU University Hospital, Munich, Germany.

Christian Hagl (C)

Department of Cardiac Surgery, LMU University Hospital, Munich, Germany.

Dominik Joskowiak (D)

Department of Cardiac Surgery, LMU University Hospital, Munich, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH